Analysis of the treatment of ovarian cancer patients with neo-adjuvant chemotherapy - preliminary results

Introduction: Primary surgery and adjuvant chemotherapy is the standard treatment in ovarian cancer patients. Neo-adjuvant chemotherapy is one of the treatment modes in patients with a poor general condition or advanced disease, not adjustable for primary surgery. The purpose of this study was to evaluate if the efficacy of this new option of therapy is comparable to the standard method.

Materials and methods: 319 ovarian cancer patients, FIGO Stage III and IV, have been analyzed. Within this group, 50 women were treated with neo-adjuvant chemotherapy. 18 patients were operated after three cycles of neo-adjuvant chemotherapy, and 32 patients--after six cycles. Results of treatment were evaluated, including disease-free survival, and number of complications. Factors that may influence the treatment results were also analyzed.

Results: Median disease-free survival in the group treated with adjuvant chemotherapy (group 3), and operated on after three cycles of neo-adjuvant chemotherapy (group 1), were 19 and 20 months, respectively. For the group operated on after six cycles of neo-adjuvant chemotherapy (group 2), median disease-free survival was 15 months (p = 0.27). The following factors have been found to influence treatment results: optimal cytoreduction and tumor grading. There was no difference in complication rates among the three analyzed groups.

Ovarian cancer; Interval debulking surgery; Neoadjuvant chemotherapy

[1] Didkowska J., Wojciechowska U., Tarkowski W., Zatonski W "Cancer in Poland in 2000. Polish National Cancer Registry. Department of Epidemiology and Cancer Prevention. The Maria Sklodowska-Curie Memorial Cancer Center". Warsaw 2002.

[2] Heintz A.P., Hacker N.F., Berek J.S. et al.: "Cytoreductive surgery in ovarian carcinoma: Feasibility and morbidity". Ohstet. Gynecol., 1986, 67, 783.

[3] Hoskins W.J., Bundy B.N., Thigpen J.T. et al.:'The influence of cytoreductive surgery on recurrence-free interval and survival in small volume Stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study". Gynecol. Oncol., 1992, 47, 159.

[4] van der Burg M.E., van Lent M., Buyse M. et al.: "The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer". N. Engl. J. Med., 1995, 332, 629.

[5] Look M., Chang D., Sugarbaker P.H.: "Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum''. Int. J. Gynecol. Cancer, 2004, 14, 35.

[6] Bristow R.E., Tomacruz R.S., Armstrong D.K. et al.: "Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era A meta analysis". J. Clin. Oncol., 2002, 20, 1248.

[7] Brockbank E.C., Ind T.E.J.. Barton D.P.J. et al.: "Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer". Int. J. Gynecol. Cancer, 2004, 14, 42.

[8] Lawton F.G., Redman C.W., Luesley D.M., Chan K.K., Blackledge G.: "Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer". Ohstet. Gynecol., 1989, 73, 61.

[9] Jacob J.H., Gershenson D.M、Morris M., Copeland L.J., Bruke T.W., W harton J.T.: "Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer". Gynecol Oncol., 1991,42, 146.

[10] Surwit E.,C hilders J.,A tlas I. et al.: "Neoadjuvant chemotherapy for advanced ovarian cancer". Int. J. Gynecol. Cancer, 1996, 17, 393.

[11] Schwartz P.E., Rutherford T.J., Chambers J.T., Kohorn E.l., Thiel R.P.: "Neoadjuvant chemotherapy for advanced ovarian cancer: long term survival". Gynecol. Oneal., 1999, 72, 93.

[12] Morice P., Dubemard G., Rey A. et al.: "Results of interval debulking surgery compared with primary debulk:ing surgery in advanced stage ovarian cancer". J. Am. Coll. Surg., 2003, 197, 955.

[13] Kuhn W., Rutke S., Spiithe K. et al.: "Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage Ilic ovarian carcinoma". Cancer, 2001, 92, 2585.

[14] Allen D.G., Coulter J.: "Survival of patients with epithelial ovarian cancer and the effect of lymphadenectomy in those with stage 3 disease". Aust., N.Z.J. Ohstet. Gynecol., 1999, 39, 420.

[15] Di Re F., Baiocchi G, Fontanelli R. et al.: "Systematic pelvic and paraaortic limphadenectomy for advanced ovarian cancer: prognos tic significance of node metastases". Gynecol. Oncol., 1996, 62, 360.

[16] McGuire W.P., Hoskins W.J., Brady M.F. et al.: "Cyclophosphamide and cisplatine compared with paclitaxel and cisplatin in patients with stage III and Stage IV ovarian cancer". N. Engl. J Med., 1996, 334, 1.

[17] Piccard M.J., Bertelsen K., James K. et al.: "Randomized intergrouptrial of cisplatin - paclitaxel versus cisplatin - cyc!ophosphamide in women with advanced epithelial ovarian cancer: threeyear results". J. Natl. Cancer Inst., 2000, 92, 699.